Establishing virtual bioequivalence and clinically relevant specifications using in vitro biorelevant dissolution testing and physiologically-based population pharmacokinetic modeling. case example: Naproxen
2020 ◽
Vol 143
◽
pp. 105170
◽
2016 ◽
Vol 5
(9)
◽
pp. 475-483
◽
2016 ◽
Vol 100
(6)
◽
pp. 761-769
◽
2018 ◽
Vol 107
(5)
◽
pp. 1330-1341
◽
2020 ◽
Vol 3
(3)
◽
pp. 444-454
◽
2019 ◽
Vol 8
(9)
◽
pp. 654-663
◽
2009 ◽
Vol 73
(1)
◽
pp. 107-114
◽
2016 ◽
Vol 33
(7)
◽
pp. 1657-1670
◽